AbbVie Inc (ABBV)vsIm Cannabis Corp (IMCC)
ABBV
AbbVie Inc
$288.85
-2.05%
HEALTHCARE · Cap: $521.11B
IMCC
Im Cannabis Corp
$0.75
-5.36%
HEALTHCARE · Cap: $1.52M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 144026% more annual revenue ($66.01B vs $45.80M). ABBV leads profitability with a 15.7% profit margin vs -39.1%. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
IMCC
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-88.0%
Fair Value
$156.84
Current Price
$288.85
$132.01 premium
Margin of Safety
+82.8%
Fair Value
$6.85
Current Price
$0.75
$6.10 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -119.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : IMCC
The strongest argument for IMCC centers on Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : IMCC
The primary concerns for IMCC are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a mature stock while IMCC is a turnaround play — different risk/reward profiles.
IMCC carries more volatility with a beta of 2.21 — expect wider price swings.
ABBV is growing revenue faster at 10.3% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 31/100), backed by strong 15.7% margins and 10.3% revenue growth. IMCC offers better value entry with a 82.8% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Im Cannabis Corp
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
IM Cannabis Corp. The company is headquartered in Tel Aviv-Yafo, Israel.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?